Pfizer (PFE) Plans Price Increases on About 80 Medicines Despite Broader Pricing Deals

Pfizer Inc. (NYSE:PFE) is included among the 13 Best January Dividend Stocks to Invest in.

Pfizer (PFE) Plans Price Increases on About 80 Medicines Despite Broader Pricing Deals

Pfizer Inc. (NYSE:PFE) is among the drugmakers planning to raise prices on some medicines starting January 1. The increases will affect about 350 drugs, even as President Donald Trump has reached agreements with 14 pharmaceutical companies to lower prices on certain treatments for the government’s Medicaid program and for cash-paying patients.

Pfizer Inc. (NYSE:PFE) announced the largest number of list price hikes, covering roughly 80 medicines. The list includes the cancer drug Ibrance, the migraine treatment Nurtec, and the COVID therapy Paxlovid. Some hospital-administered drugs, such as morphine and hydromorphone, are also included.

Most of Pfizer’s price increases are under 10%. One exception is a 15% hike for the COVID vaccine Comirnaty. A few lower-priced hospital drugs are seeing much steeper moves, with prices rising more than four times. Pfizer said it adjusted the average list price of its innovative medicines and vaccines for 2026 to remain below the overall rate of inflation. The company made the following remark:

“The modest increase is necessary to support investments that allow us to continue to discover and deliver new medicines as well as address increased costs throughout our business.”

According to a report by Reuters, drugmakers plan to raise U.S. prices on at least 350 branded medicines. The list includes vaccines for COVID, RSV, and shingles, along with major cancer drugs such as Ibrance. The data was provided exclusively by healthcare research firm 3 Axis Advisors, even as pressure from the Trump administration continues.

The number of planned price increases for 2026 is higher than at the same point last year, when companies outlined hikes for more than 250 drugs. This year’s median increase sits around 4%, in line with 2025 levels.

Pfizer Inc. (NYSE:PFE) is a research-driven biopharmaceutical company with operations around the world. It focuses on discovering, developing, manufacturing, and marketing medicines and vaccines across a wide range of therapeutic areas.

While we acknowledge the potential of PFE as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than PFE and that has a 100x upside potential, check out our report about the cheapest AI stock.

READ NEXT: 12 Best Income Stocks to Buy Now and 20 Best Performing Dividend Stocks in 2025

Disclosure: None.